Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck | 15/02/2024 |  |
| Important safety information on Cephalosporins in Ethiopia (Safety Notification_Cephalosporins and risk of seizure) | 01/03/2023 | |
Important safety information on Cephalosporins in Ethiopia (Safety Notification_Cephalosporins and risk of neurotoxicity) |
07/03/2023 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Ethiopia |
09/09/2023 | |
| Important safety information on Cefuroxime sodium in Ethiopia (Safety Notification_Cefuroxime Class 4 Defect MHRA) | 30-10-2023 | |
| Important safety information on Dolutegravir in Ethiopia (Safety Notification_Korean label update for Dolutegravir containing products) | 01-11-2023 | |
| Tafenoquine Educational program_TRuST Observational Study_Talking Points | 13/10/2023 | |
| Tafenoquine Educational program_TRuST_Treatment Schedule for CQ and TQ_1 | 13/10/2023 | |
| Tafenoquine Educational program_TRuST_Treatment Schedule for CQ and TQ_2 | 13/10/2023 | |
| Tafenoquine Educational program_G6PD folder | 13/10/2023 | |
| Tafenoquine Educational program_Module 4_Unit 1_Quick guide on G6PD testing | 13/10/2023 | |
| Tafenoquine Educational program_Module 4_Unit 2_Quick guide on G6PD testing | 13/10/2023 | |
| Tafenoquine Educational program_Module 4_Unit 3_Quick guide on G6PD testing | 13/10/2023 | |
| Important safety information on Topical Corticosteroids containing products in Ethiopia | 15-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Ethiopia (Initial Safety Notification Engerix-B and Myelitis_November 2023) | 17-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Ethiopia (Updated Safety Notification Engerix-B and Myelitis_December 2023) | 02-01-2024 | |
